Neutrophilic airway inflammation disproportionate to bacterial burden
Elastase and proteases damage airway architecture
Progressive bronchiectasis develops
Exacerbation triggers
Viral respiratory infection
Identified in ~22% of exacerbations
Rhinovirus, influenza, RSV most common
New or resistant bacterial acquisition
New Pseudomonas strain or MRSA
NTM superinfection
Reduced mucociliary clearance
Dehydration
Non-adherence to airway clearance
Systemic stress
Surgical procedures
Pregnancy
Therapeutic Considerations
Antibiotic selection rationale
Dual therapy targets Pseudomonas aeruginosa
Synergy between aminoglycoside and beta-lactam
Reduces emergence of resistance
Culture-directed adjustment
Susceptibility testing essential for appropriate coverage
Burkholderia cepacia: intrinsically resistant to many agents
NTM requires species-specific multi-drug regimen
Duration evidence base
RCT (n=982): 10 days noninferior to 14 days in responders
21 days not superior to 14 days in non-responders
Cochrane review supports IV antibiotics over inhaled alone for moderate-severe exacerbations
CFTR modulator impact on management
ETI reduces exacerbation frequency dramatically
Patients on ETI who exacerbate may have more subtle presentations
Providers broadening assessment criteria in HEMT era
ETI does not eliminate exacerbation risk
Patients with advanced established bronchiectasis still exacerbate
Continue standard exacerbation treatment alongside modulators
Lung transplantation considerations
Referral threshold: FEV1 declining to 30% predicted or rapid decline
CFF consensus guidelines for advanced CF lung disease
Early referral allows adequate evaluation time
Avoid pleurodesis in transplant candidates
Pleural symphysis increases surgical complexity
Chest tube drainage without pleurodesis for pneumothorax
Inhaled antibiotic prophylaxis
Inhaled tobramycin 300 mg BID alternating months
Reduce exacerbation frequency in Pseudomonas-colonized patients
Aztreonam for inhalation 75 mg TID alternating months
Alternative to inhaled tobramycin
Patient Discharge Instructions
copy discharge instructions
Understanding your CF exacerbation
You have been treated for a worsening of your cystic fibrosis lung condition
This is called a pulmonary exacerbation
Your lungs became more congested and infected, requiring stronger treatment
Recovery takes time
Symptoms typically improve within 7-10 days of starting antibiotics
Your lung function (FEV1) may not return to your usual level right away
Some patients remain below their best lung function for weeks to months
Your antibiotic treatment at home
Take all antibiotics exactly as prescribed and for the full course
Do not stop early even if you feel better
Contact your CF clinic if you experience side effects
IV antibiotics at home require careful nursing follow-up
Keep all scheduled nursing visits for line care and blood tests
Report any redness, swelling, or pain at your IV site
Airway clearance is critical
Perform airway clearance at least twice daily, more if advised
Use your vest, PEP device, or prescribed method consistently
Do not skip sessions even if you feel tired
Take your nebulized medications in the correct order
Bronchodilator first, then dornase alfa or hypertonic saline, then airway clearance
Continue all your usual CF medications
Do not stop your CFTR modulator (Trikafta/Kaftrio or other)
This medication reduces your risk of future exacerbations
Take your pancreatic enzymes with every meal and snack
Continue your vitamins as prescribed
Nutrition and hydration
Eat high-calorie, high-protein foods to help recovery
Drink plenty of fluids to keep mucus thin
Contact your dietitian if appetite remains poor
If you have CF-related diabetes, monitor your blood sugar closely
Your insulin needs may be higher than usual during recovery
Follow-up appointment
CF clinic visit within 1-2 weeks of completing antibiotics
Bring your home spirometry readings if available
Repeat lung function test at clinic visit
Influenza and COVID-19 vaccines recommended annually
Infection control
Avoid contact with other people who have CF
CF bacteria can be transmitted person-to-person
2-metre separation rule applies at clinic and hospital
Return to emergency department immediately if
You cough up blood in large amounts (more than a teaspoon)
You develop sudden chest pain with difficulty breathing
Your oxygen levels drop or you feel severely short of breath
You develop fever above 38.5°C that is not improving
You cannot eat, drink, or take your medications
You feel confused, extremely weak, or cannot stay awake
References
Guidelines and key sources
Flume PA, Mogayzel PJ, Robinson KA, et al.
Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations
American Journal of Respiratory and Critical Care Medicine, 2009
Primary guidelines for exacerbation management
Flume PA, Mogayzel PJ, Robinson KA, et al.
Cystic Fibrosis Pulmonary Guidelines
American Journal of Respiratory and Critical Care Medicine, 2010
Chronic medications management
Kapnadak SG, Dimango E, Hadjiliadis D, et al.
Cystic Fibrosis Foundation Consensus Guidelines for the Care of Individuals With Advanced Cystic Fibrosis Lung Disease
Journal of Cystic Fibrosis, 2020
Advanced disease and transplant referral guidance
King CS, Brown AW, Aryal S, Ahmad K, Donaldson S.
Critical Care of the Adult Patient With Cystic Fibrosis
Chest, 2019
ICU management and complications
Landmark trials and systematic reviews
Hurley MN, Smith S, Flume P, Jahnke N, Prayle AP.
Intravenous Antibiotics for Pulmonary Exacerbations in People With Cystic Fibrosis
Cochrane Database of Systematic Reviews, 2025
Duration evidence: 10 days noninferior to 14 days in responders
Smith S, Rowbotham NJ, Charbek E.
Inhaled Antibiotics for Pulmonary Exacerbations in Cystic Fibrosis
Cochrane Database of Systematic Reviews, 2022
Inhaled vs. IV antibiotic evidence base
Middleton PG, Mall MA, Drevinek P, et al.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis With a Single Phe508del Allele
New England Journal of Medicine, 2019
ETI reduces exacerbation rates ~63%
Supporting evidence
Hassanzad M, Kiani A, Abedini A, et al.
Lung Ultrasound for the Diagnosis of Cystic Fibrosis Pulmonary Exacerbation
BMC Pulmonary Medicine, 2021
AUROC 0.966 for lung ultrasound vs. 0.483 for CXR
Fathima P, Pan E, Marsh J, et al.
Characteristics, Treatment, and Lung Function Outcomes of Pulmonary Exacerbations in CF
European Respiratory Journal, 2025
44% remain below baseline FEV1 at 60 days
Toporek A, Patel S, Psoter KJ, et al.
Provider Practices in Pulmonary Exacerbations of CF in the Era of Highly Effective Modulator Therapy
Annals of the American Thoracic Society, 2025
HEMT era practice patterns and evolving presentation
Ong T, Ramsey BW.
Cystic Fibrosis: A Review
Journal of the American Medical Association, 2023
Comprehensive contemporary review
Shteinberg M, Haq IJ, Polineni D, Davies JC.
Cystic Fibrosis
Lancet, 2021
Epidemiology and pathophysiology reference
Garcia B, Flume PA.
Pulmonary Complications of Cystic Fibrosis
Seminars in Respiratory and Critical Care Medicine, 2019
Hemoptysis and pneumothorax management
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.